JPS6360862B2 - - Google Patents
Info
- Publication number
- JPS6360862B2 JPS6360862B2 JP56068381A JP6838181A JPS6360862B2 JP S6360862 B2 JPS6360862 B2 JP S6360862B2 JP 56068381 A JP56068381 A JP 56068381A JP 6838181 A JP6838181 A JP 6838181A JP S6360862 B2 JPS6360862 B2 JP S6360862B2
- Authority
- JP
- Japan
- Prior art keywords
- latex
- fibrinogen
- agglutination reaction
- sample
- fibrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 claims abstract description 36
- 239000004816 latex Substances 0.000 claims abstract description 21
- 229920000126 latex Polymers 0.000 claims abstract description 21
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 20
- 108010073385 Fibrin Proteins 0.000 claims abstract description 14
- 102000009123 Fibrin Human genes 0.000 claims abstract description 14
- 229950003499 fibrin Drugs 0.000 claims abstract description 14
- 230000004520 agglutination Effects 0.000 claims abstract description 13
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 6
- 239000013060 biological fluid Substances 0.000 claims abstract description 5
- 108010049003 Fibrinogen Proteins 0.000 claims description 23
- 102000008946 Fibrinogen Human genes 0.000 claims description 23
- 229940012952 fibrinogen Drugs 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 239000002245 particle Substances 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 19
- 108090000190 Thrombin Proteins 0.000 claims description 9
- 229960004072 thrombin Drugs 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 8
- 239000000178 monomer Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 239000003998 snake venom Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 3
- 238000001514 detection method Methods 0.000 abstract description 8
- 108010073651 fibrinmonomer Proteins 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 3
- 239000012530 fluid Substances 0.000 abstract description 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 239000000872 buffer Substances 0.000 description 14
- 239000004471 Glycine Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 7
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 108010039627 Aprotinin Proteins 0.000 description 2
- 108010027612 Batroxobin Proteins 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 229960002210 batroxobin Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003311 flocculating effect Effects 0.000 description 1
- 239000008125 glucin Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analyzing Materials By The Use Of Magnetic Means (AREA)
Description
æ¬çºæã¯ãè¡æŒ¿åã³ä»ã®çç©åŠç液äœã®ãã€ã
ãªã³ã¢ãããŒïŒFSïŒãæ€åºåã³æž¬å®ããæ¹æ³ã«
é¢ããã è¡æ çæã®æ©æ蚺æã¯ã蚺æåŠäžèããéèŠæ§
ãæããããã®ããã«ã¯ãæœåšçã«é²è¡ããŸã å€
èŠäžæãããªèšåºçç ç¶ãçããªãååºéçšãè
å¥ããªããã°ãªããªããåŸæ¥ç°¡åãªæ¹æ³ã§ãååº
ç³»ã®æŽ»ååçæç©ãæ©æ段éã«æ€åºããããã«
ã¯ãææãªæ¹æ³åã¯èšåºäžæçšãªæ¹æ³ã¯ååšããª
ããååºéçšã®çŽæ¥çæ瀺è¬ã®ïŒã€ã¯FSã§ããã
ããã¯ããã³ãã³ã®ãã€ããªãã²ã³ã«å¯Ÿããäœçš
ã«ãã€ãŠçãããããããªéã®FSã¯è¡æ¶²äžã«å
åšããéå°éã®ãã€ããªãã²ã³ã«ãã€ãŠå®å®ã«ãª
ããè¡ç®¡ç³»äžã§æ²çããªãã§æº¶è§£ããŠåŸãããã
ããæ 蚺ææ³ã®èª²é¡ã¯ã溶解圢ã§åŸªç°ããããã
ãªéã®ãã®FSãéå°éã®ãã€ããªãã²ã³ã®ååš
ã§æ€åºåã³æž¬å®ããããšã§ãããFSãããã€ã
ãªãã²ã³ãšã¯ååéã«ãã€ãŠãæåã®æ§é ã«ãã€
ãŠãåºå¥ããããšãã§ããªãã®ã§ãåžžçšã®çååŠ
çæ€åºæ³ã䜿çšããããšã¯ã§ããªãã FSãæ€åºãã次ã®æ¹æ³ã¯ãæ¢ã«å ¬ç¥ã§ããïŒ (1) ãã€ããªãã²ã³ã«æ¯ããŠFSã®å€§ããæ²æ®¿åŸ
åãå©çšããæ²æ®¿æ³ãäŸãã°ãã¬ãŒã³
ïŒBreenïŒåã³ããŠãŒãªã¹ïŒTullisïŒã«ãããš
ã¿ããŒã«è©ŠéšãAnnals of Internal
Medicineã第69å·»ã第1197ã1206é ïŒ1968
幎ïŒãåã¯ããŒãã¢ããã¹ããŒ
ïŒNiewiarowskiïŒåã³ã°ã¬ãã€ã
ïŒGurewichïŒã«ããããã¿ãã³ç¡«é žå¡©è©ŠéšãJ.
Lab.Clin.Med.ã第77å·»ã第665ã676é ïŒ
ïŒ1971幎ïŒãããããã¯åãããã€ããªã³ç¹ç¶ã
ååã«èå¥ããããã«ã¯ãã³ãã€ãç¶ã®çè²ç²
åãäŸãã°ã«ãŒãã³ç²åã䜿çšããïŒãã€ãå ¬
éç¹èš±ç¬¬2528381å·æ现æžïŒãç¹æã§ã¯ãªãæ²æ®¿
ã®å±éºãšå ±ã«ããããã®æ¹æ³ã¯éæã§ãããã€
å®æ§çæ瀺ãåŸãããã®ã«éããªãæ¬ ç¹ãæã
ãã (2) ã²ã«é®æã¯ãããã°ã©ãã€ãŒããã¬ããã€ãŒ
ïŒFletcherïŒåã³ã¢ã«ã¯ã€ãŒãšã«ã·ãã¯
ïŒAlkjaersigïŒïŒRecentâAdvancesin
ThrombosisãL.Poller Editorããã³ãã³åšã
1973幎ãLivingstoneâChurchillçãåã³ãã€
ããªã³ã¢ã¬ããŒãŒã§ã®èŠªååã¯ãããã°ã©ãã€
ãŒãããŒãïŒHeeneïŒåã³ããã¢ã¹
ïŒMatthiasïŒïŒThromb.Researchã第ïŒå·»ã第
137ã154é ïŒ1973幎ïŒãããããã®æ¹æ³ã¯ããã€
ããªãã²ã³ã§é«ååã®é¯äœã圢æããFSã®æ§
質ãåã¯FSã®èªå·±äŒåã«åºã¥ãããããã®æ¹
æ³ã¯èšåºäžã®åžžæ³ãšã¿ãªãããšã¯ã§ããªããã
ããšããã®ã該æ¹æ³ã¯å®çšçã§ã¯ãªãããã€å
åã«ææã§ããªãããã§ããã (3) æŽã«FSã®èªå·±äŒåã«åºã¥ãæ¹æ³ã¯å ¬ç¥ã§ã
ããã©ãŒãŽïŒLargoïŒãããŒã©ïŒHellerïŒåã³
ã·ãŠãã©ãŠãïŒStraubïŒïŒBloodã第47å·»ã第
ïŒå·ïŒ1976幎ïŒãããã®æ¹æ³ã§ã¯å ã¥FSãè² è·
ããèµ€è¡çã調æŽãã次ãã§ããã¯æ€æ»ãã¹ã
è©Šæäžã®æº¶è§£ããFSã®ååšã§åéåå¿ããã
ãã®æ¹æ³ã¯ãæ®ã«äžååãªæ床ã®ããã«åãã
ãã«èšåºçè©ŠéšãšããŠã¯å®æœãããªãã (4) 14ââã°ãªã·ã³ãšã¹ãã«ã®å°å ¥ããã¹ã«ãŒ
ïŒKiskerïŒåã³ã©ãã·ãŠïŒRushïŒïŒJ.Clin.
Invest.ã第50å·»ã第2235é ã1971幎ãããã¢ã¯
ã¿ãŒãçšããŠãæŸå°èœã®èšå·ãä»ãã14â
âã°ãªã·ã³ãšã¹ãã«ãç¹å¥ã«FSäžã«å°å ¥ã
ãããšãã§ããããã®æ¹æ³ã¯ææã§ã¯ãããã
äœãå®çšçã§ã¯ãªããæŸå°èœãåæ±ãéé¢åãª
æ¹æ³åã³è²»çšã®ãããè£ çœ®ãå¿ èŠãšããã æ¬çºæã®ç®çã¯ãå ¬ç¥æ¹æ³ã®æ¬ ç¹ãé€ããã€ãŸ
ãç°¡åã§è¿ éã«å®æœããããšãã§ããè²»çšã®ãã
ãè£ çœ®ãå¿ èŠãšãããå®æ§çãåå®éç䞊ã³ã«å®
éç枬å®ã«é©åœãªåçšã®æ¹æ³ãåŸãããšã§ããã ãšããã§æå€ãªããšã«ããã€ããªã³ã¢ãããŒ
ïŒFSïŒã¯ãã€ããªãã²ã³åã³ä»ã®è¡æŒ¿èçœè³ªãšç°
ãªããçæ°Žæ§ã©ããã¯ã¹ç²åã«å¯ŸããŠå€§ãã芪å
åã瀺ãããšãå€æããã æ¬çºæã«ããçç©åŠç液äœã®ãã€ããªã³ã¢ãã
ãŒãæ€åºåã³æž¬å®ããæ¹æ³ã¯è©Šæ液äœãã©ããã¯
ã¹ãšå¹é€ããåéåå¿ã枬å®ããããšãããªãã 奜ãŸããã¯æ¬çºæã«ããã°ãç²ååã¯ç¹æ»Žã¯å
é枬å®è£ 眮ã§æž¬å®ããå Žåã«ã¯å¹³åçŽåŸ0.05ã
1.5ÎŒãæã«å¥œãŸããã¯0.5ã1.2ÎŒãå 床èšã§æž¬å®ã
ãå Žåã«ã¯å¹³åçŽåŸ0.07ã0.1ÎŒãæããçæ°Žæ§ã©
ããã¯ã¹ã䜿çšãããããããªããããã®ç¯å²ä»¥
å€ã§ååšããçŽåŸãæããã©ããã¯ã¹åã¯ç¹æ»Žã
é©åœã§ããããã®ããã«ããŠã0.03ã10ÎŒã®ã©ã
ã¯ã¹ç²åãçšããŠããªãæçšãªçµæãåŸãããã
ãã®å Žåã©ããã¯ã¹ãšã¯ãæ¬çºæç¯å²å ã§ã¯å€©ç¶
åã¯åæã®ãŽã ç²åãæ®ã«æ°Žã«åæ£ããäŸãã°ã¹
ãããŒã«åã¯ã¹ãããŒã«åã³ãã¿ãžãšã³ãããªã
éåäœç²ååã¯å ±éåäœç²åã®ãšãã«ãžãšã³åã³
ãã®ä»ã®åæ£æ¶²ã§ãããæ¬çºæã«ã¯ãç²ååã¯ç¹
滎ã¯çæ°Žæ§è¡šé¢ãæããã®ãéèŠã§ããã è©Šæ液äœãšã©ããã¯ã¹ãšã®å¹é€ã¯ã奜ãŸããã¯
é«æž©åºŠã§è¡ãªãã奜ãŸããã¯æž©åºŠ30ã40âã§ã
ãããããšããã®ããã®å Žååå¿ã¯æãè¿ éã«é²
è¡ããããã§ãããããããªãããé©åœã«å»¶é·ã
ãå¹é€æéã§ã¯ãããããäœã枩床ãåã¯å Žåã«
ãããªãè¥å¹²ããããã倧ãã枩床ã䜿çšããã
ãšãã§ããã枩床37âã§ã®äºå¹é€æéã¯ã奜ãŸã
ãã¯ïŒã15åéã§ããããã®ç¯å²ãäžããšåçŸæ§
ã¯åé¡ã§ããããã®ç¯å²ãè¶ãããšå©ç¹ã¯åŸãã
ãªãã åå¿ã¯å¥œãŸããã¯ç·©è¡æº¶æ¶²äžã§è¡ãªãããã®å Ž
åPH7.0ã9.0ãç¹ã«é©åœã§ããããšãå€æããã
奜ãŸããã¯PH7.7ã8.7ã§ãããææã®PHç¯å²ã調
ç¯ããããã«ã¯ãåèšç¯å²å ã§äœçšããä»»æã®ç·©
è¡ç©è³ªãé©åœã§ããã奜ãŸããã¯ã°ãªã·ã³ïŒé£å¡©
âç·©è¡å€ã§ãããç·©è¡å€ã®æ¿åºŠã¯å¥œãŸããã¯0.05
ã0.5Mã§ããã æ¬çºææ¹æ³ã®å®æ§çå®æœã¯ã奜ãŸããã¯æ€æ»ã
ã¹ãè©ŠæãäŸãã°è¡æŒ¿ãé©åœãªã©ããã¯ã¹ç²åæ°Ž
æžæ¿æ¶²ãšå¹é€ããããã«ããŠè¡ãªãããã®å Žå奜
ãŸããã¯åèšã®æž©åºŠåã³æéã®ç¯å²ãç¶æããã ç¶ããŠåå¿æ··åç©ããæ éã«æ¯çªãããåã¯
åã ã®å Žã«åããããŠããŠãããéæãåã¯åå
ã«èŠ³å¯ããããã«æè²ã«è²ãæœããããŠããŠãã
ãè©Šéšãã¬ãŒãäžã«æ»Žäžããè©Šéšãã¬ãŒããå圢
ã«åãããæ€æ»æ¶²äœäžã«FSãååšãããšãç²å
ã®å£å¡åãçããããã¯èçŒã§èŠãããšãã§ã
ããåå¿ãååã«èŠåŸãããã«ã¯ç²åæžæ¿æ¶²ãé
å¿åé¢ããŠãããããã®å Žååéåå¿ç²åã¯éå
éåå¿ç²åãããè¿ éãã€ãŸã容æã«æ²æ®¿ããã
奜ãŸããã¯åå¿ã¯ãã¯ã滎å®ãã¬ãŒãã§è¡ãªã€ãŠ
ããããããã¯èªåããéããããã«ä»å çã«é
å¿åé¢ããããšãã§ããã æ¹æ³ãåå®éçã«å®æœããããã«ã¯ãé£ç¶åžé
溶液ã調補ãããããå ¬ç¥éã®FSãå«æããè©Š
æãšæ¯èŒããããã®å Žå奜ãŸããã¯ãªãèçŒã§ã¿
ãããšã®ã§ããåéåå¿ãçããããæé«åžé段
éã«åå¿ã®æ€åºç¯å²ãä¹ããããã®æ€åºç¯å²ã¯ã
å ¬ç¥FSå«éãæããæšæºç©ãåžéã«ããã®ãšå
ãæ¹æ³ã§äœ¿çšããããšã«ãã枬å®ããããšãã§ã
ããå®éçã«ã¯æ¹æ³ã¯ãåé枬å®è£ 眮åã¯å 床èš
ã®äœ¿çšã§è¡ãªãããšãã§ããã æ¬çºææ¹æ³ã«ãã€ãŠæž¬å®ããããšã®ã§ãããã€
ããªã³ãšã¯ããããã溶解æ§ãã€ããªã³ãã€ãŸã
ãã€ããªã³ã¢ãããŒãæ¢ã«äžç·ã«ãªã€ããã€ããª
ã³ã«ãªã€ãããè¡šé¢ã«ãªãçæ£ã®ãã€ããªã³ã¢ã
ããŒãæãããåã¯ãã¥ãã«ãããã€ããªã³ã¢ã
ããŒã®ããã«æåãããã€ããªã³ã®äžé圢ã§ã
ãããã®æº¶è§£æ§ãã€ããªã³ã«ãã€ãŠåãããã«ã
ãŠåãåéåå¿ãåŸãããããæ åãããã«ããŠ
ææ¡ãããã ã©ããã¯ã¹ã¯ã奜ãŸããã¯ç²åå«é0.1ã10ïŒ ã
ç¹ã«0.5ãïŒïŒ ãæãããã©ããã¯ã¹ãšè©Šæ溶液
ãšã¯ã容éå²åçŽïŒïŒ10ã10ïŒïŒã§æ··åãããïŒ
ïŒ ã®æžæ¿æ¶²ã䜿çšããå Žåã«ã¯ãæ··åå²åã¯å¥œãŸ
ããã¯ïŒïŒïŒãïŒïŒïŒã§ããã æ¬çºæã¯ããã€ããªãã²ã³ãçŽæ¥ã«æž¬å®ããã
ãã«ãé©åœã§ããããã®å Žåã«ã¯ãè©Šæã®ãã€ã
ãªãã²ã³å šéšããå ã¥å ¬ç¥æ¹æ³ã§ãã€ããªã³ã¢ã
ããŒã«å€æãããå€æã¯ãé©åœãªé µçŽ ã§è¡ãªãã
é©åœãªé µçŽ ã¯äŸãã°ããã³ãã³åã¯èæ¯ãäŸãã°
ãããããœãã³ïŒBatroxobinïŒã§ãããå¹³è¡è©Š
æã§æŽã«ãã€ããªã³ã¢ãããŒã®å«éã確ãããå Ž
åã«ã¯ãæ¯èŒè©Šæäžã®æž¬å®FSå«éãšé µçŽ åŠçã®
è©Šæãšã®éã®å·®ç°ãããã€ããªãã²ã³å«éãåŸã
ããã奜ãŸããã¯æ¬çºæã®ãã®å®æœåœ¢åŒã§ã¯ãã
ã€ããªãã²ã³ã®ãã€ããªã³ã¢ãããŒãžã®å€æã¯ã©
ããã¯ã¹ç²åã®ååšã§è¡ãªãã 次ã«å®æœäŸã«ã€ãæ¬çºæã説æããã äŸ ïŒ (A) å¥åº·ãªäººããEDTA1mgïŒmlåã³ã¢ãããã
ã³0.1mgïŒmlã®ååšäžã«è¡æ¶²ããšãã2000gã§10
åéé å¿åé¢ãããè¡æŒ¿ããã®äžæŸã¿ïŒmlã37
âã«ããããã³ãã³ããªãã¹ã¿ãžã³
ïŒopostasinïŒãããã·ãŠç€Ÿã0.05åäœãšæ··åã
ãã0.2mlã®æŽé€éãååºããäºãæºåããã
ããªã³ããªã¯ãšãã³ïŒLiqueminïŒãããã·ãŠ
瀟ãïŒåäœåã³ãã«ãžã³ãã·ã°ãïŒSigmaïŒã
0.2åäœãå«æããå°ç®¡ã«ããããã§ãšããæŽ
é€éã®ååºãã®æç¹ãšããŠã¯ã次ã®æéãéžã
ã ïŒããã³ãã³ã®æ·»å çŽåŸã30ç§ãïŒåãïŒå
åã³ïŒåããã®ããã«ããŠãçš®ã ã®éã®FSã
å«æããè©ŠæãåŸãããããã¯ä»ã®æ€æ»ã«å®€æž©
ã§ä¿åããã (B) è©Šæã®åžé溶液ããã°ãªã·ã³0.25ã¢ã«åã³
NaCl0.9ïŒ ãå«æãã1nâNaOHã§PH8.2ã«èª¿
ç¯ããã°ãªã·ã³ïŒNaClâç·©è¡å€ã§èª¿è£œããã
å¹³åç²åŸ0.8ÎŒãæãã10ïŒ ã®æžæ¿æ¶²ã®åœ¢ã®ããª
ã¹ãããŒã«ã©ããã¯ã¹ãã»ã«ãïŒServaïŒç€Ÿã
ãã€ãã«ãã«ã¯åšããããã®ç·©è¡å€ã§ïŒïŒ10ã«
åžéãããããããã©ããã¯ã¹0.05mlåã³é©åœ
ãªæ¹æ³ã§äºãåžéããè¡æŒ¿è©Šæ0.05mlãæ··å
ãã37âã§10åéå¹é€ãããå°ç®¡ã®å 容ãæè²
ã«çè²ãããã©ã¹ããã¯ãã¬ãŒãã®çžäºã«å¥ã
ã«åé¢ããå Žã«å¡åžãããã¬ãŒããæ éã«ïŒå
éå転ããç¶ããŠã©ããã¯ã¹ç²åã®å£å¡åãèš
é²ãããè¡æŒ¿ã«å¯Ÿããããã³ãã³ã®äœçšæéã
å¢å€§ããã«ã€ããŠãå£å¡åã®åŒ·åºŠã倧ãããªã
ããšãå€æãããå¢å€§ããåžéã䜿çšããããš
ã«ãã€ãŠããã¹ãŠã®è©Šæã«ãªãæãããªåéå
å¿ãçããåžé溶液ãçããããããšãã§ã
ããçµæã¯ç¬¬ïŒè¡šã«èšèŒãããŠããã
ãªã³ã¢ãããŒïŒFSïŒãæ€åºåã³æž¬å®ããæ¹æ³ã«
é¢ããã è¡æ çæã®æ©æ蚺æã¯ã蚺æåŠäžèããéèŠæ§
ãæããããã®ããã«ã¯ãæœåšçã«é²è¡ããŸã å€
èŠäžæãããªèšåºçç ç¶ãçããªãååºéçšãè
å¥ããªããã°ãªããªããåŸæ¥ç°¡åãªæ¹æ³ã§ãååº
ç³»ã®æŽ»ååçæç©ãæ©æ段éã«æ€åºããããã«
ã¯ãææãªæ¹æ³åã¯èšåºäžæçšãªæ¹æ³ã¯ååšããª
ããååºéçšã®çŽæ¥çæ瀺è¬ã®ïŒã€ã¯FSã§ããã
ããã¯ããã³ãã³ã®ãã€ããªãã²ã³ã«å¯Ÿããäœçš
ã«ãã€ãŠçãããããããªéã®FSã¯è¡æ¶²äžã«å
åšããéå°éã®ãã€ããªãã²ã³ã«ãã€ãŠå®å®ã«ãª
ããè¡ç®¡ç³»äžã§æ²çããªãã§æº¶è§£ããŠåŸãããã
ããæ 蚺ææ³ã®èª²é¡ã¯ã溶解圢ã§åŸªç°ããããã
ãªéã®ãã®FSãéå°éã®ãã€ããªãã²ã³ã®ååš
ã§æ€åºåã³æž¬å®ããããšã§ãããFSãããã€ã
ãªãã²ã³ãšã¯ååéã«ãã€ãŠãæåã®æ§é ã«ãã€
ãŠãåºå¥ããããšãã§ããªãã®ã§ãåžžçšã®çååŠ
çæ€åºæ³ã䜿çšããããšã¯ã§ããªãã FSãæ€åºãã次ã®æ¹æ³ã¯ãæ¢ã«å ¬ç¥ã§ããïŒ (1) ãã€ããªãã²ã³ã«æ¯ããŠFSã®å€§ããæ²æ®¿åŸ
åãå©çšããæ²æ®¿æ³ãäŸãã°ãã¬ãŒã³
ïŒBreenïŒåã³ããŠãŒãªã¹ïŒTullisïŒã«ãããš
ã¿ããŒã«è©ŠéšãAnnals of Internal
Medicineã第69å·»ã第1197ã1206é ïŒ1968
幎ïŒãåã¯ããŒãã¢ããã¹ããŒ
ïŒNiewiarowskiïŒåã³ã°ã¬ãã€ã
ïŒGurewichïŒã«ããããã¿ãã³ç¡«é žå¡©è©ŠéšãJ.
Lab.Clin.Med.ã第77å·»ã第665ã676é ïŒ
ïŒ1971幎ïŒãããããã¯åãããã€ããªã³ç¹ç¶ã
ååã«èå¥ããããã«ã¯ãã³ãã€ãç¶ã®çè²ç²
åãäŸãã°ã«ãŒãã³ç²åã䜿çšããïŒãã€ãå ¬
éç¹èš±ç¬¬2528381å·æ现æžïŒãç¹æã§ã¯ãªãæ²æ®¿
ã®å±éºãšå ±ã«ããããã®æ¹æ³ã¯éæã§ãããã€
å®æ§çæ瀺ãåŸãããã®ã«éããªãæ¬ ç¹ãæã
ãã (2) ã²ã«é®æã¯ãããã°ã©ãã€ãŒããã¬ããã€ãŒ
ïŒFletcherïŒåã³ã¢ã«ã¯ã€ãŒãšã«ã·ãã¯
ïŒAlkjaersigïŒïŒRecentâAdvancesin
ThrombosisãL.Poller Editorããã³ãã³åšã
1973幎ãLivingstoneâChurchillçãåã³ãã€
ããªã³ã¢ã¬ããŒãŒã§ã®èŠªååã¯ãããã°ã©ãã€
ãŒãããŒãïŒHeeneïŒåã³ããã¢ã¹
ïŒMatthiasïŒïŒThromb.Researchã第ïŒå·»ã第
137ã154é ïŒ1973幎ïŒãããããã®æ¹æ³ã¯ããã€
ããªãã²ã³ã§é«ååã®é¯äœã圢æããFSã®æ§
質ãåã¯FSã®èªå·±äŒåã«åºã¥ãããããã®æ¹
æ³ã¯èšåºäžã®åžžæ³ãšã¿ãªãããšã¯ã§ããªããã
ããšããã®ã該æ¹æ³ã¯å®çšçã§ã¯ãªãããã€å
åã«ææã§ããªãããã§ããã (3) æŽã«FSã®èªå·±äŒåã«åºã¥ãæ¹æ³ã¯å ¬ç¥ã§ã
ããã©ãŒãŽïŒLargoïŒãããŒã©ïŒHellerïŒåã³
ã·ãŠãã©ãŠãïŒStraubïŒïŒBloodã第47å·»ã第
ïŒå·ïŒ1976幎ïŒãããã®æ¹æ³ã§ã¯å ã¥FSãè² è·
ããèµ€è¡çã調æŽãã次ãã§ããã¯æ€æ»ãã¹ã
è©Šæäžã®æº¶è§£ããFSã®ååšã§åéåå¿ããã
ãã®æ¹æ³ã¯ãæ®ã«äžååãªæ床ã®ããã«åãã
ãã«èšåºçè©ŠéšãšããŠã¯å®æœãããªãã (4) 14ââã°ãªã·ã³ãšã¹ãã«ã®å°å ¥ããã¹ã«ãŒ
ïŒKiskerïŒåã³ã©ãã·ãŠïŒRushïŒïŒJ.Clin.
Invest.ã第50å·»ã第2235é ã1971幎ãããã¢ã¯
ã¿ãŒãçšããŠãæŸå°èœã®èšå·ãä»ãã14â
âã°ãªã·ã³ãšã¹ãã«ãç¹å¥ã«FSäžã«å°å ¥ã
ãããšãã§ããããã®æ¹æ³ã¯ææã§ã¯ãããã
äœãå®çšçã§ã¯ãªããæŸå°èœãåæ±ãéé¢åãª
æ¹æ³åã³è²»çšã®ãããè£ çœ®ãå¿ èŠãšããã æ¬çºæã®ç®çã¯ãå ¬ç¥æ¹æ³ã®æ¬ ç¹ãé€ããã€ãŸ
ãç°¡åã§è¿ éã«å®æœããããšãã§ããè²»çšã®ãã
ãè£ çœ®ãå¿ èŠãšãããå®æ§çãåå®éç䞊ã³ã«å®
éç枬å®ã«é©åœãªåçšã®æ¹æ³ãåŸãããšã§ããã ãšããã§æå€ãªããšã«ããã€ããªã³ã¢ãããŒ
ïŒFSïŒã¯ãã€ããªãã²ã³åã³ä»ã®è¡æŒ¿èçœè³ªãšç°
ãªããçæ°Žæ§ã©ããã¯ã¹ç²åã«å¯ŸããŠå€§ãã芪å
åã瀺ãããšãå€æããã æ¬çºæã«ããçç©åŠç液äœã®ãã€ããªã³ã¢ãã
ãŒãæ€åºåã³æž¬å®ããæ¹æ³ã¯è©Šæ液äœãã©ããã¯
ã¹ãšå¹é€ããåéåå¿ã枬å®ããããšãããªãã 奜ãŸããã¯æ¬çºæã«ããã°ãç²ååã¯ç¹æ»Žã¯å
é枬å®è£ 眮ã§æž¬å®ããå Žåã«ã¯å¹³åçŽåŸ0.05ã
1.5ÎŒãæã«å¥œãŸããã¯0.5ã1.2ÎŒãå 床èšã§æž¬å®ã
ãå Žåã«ã¯å¹³åçŽåŸ0.07ã0.1ÎŒãæããçæ°Žæ§ã©
ããã¯ã¹ã䜿çšãããããããªããããã®ç¯å²ä»¥
å€ã§ååšããçŽåŸãæããã©ããã¯ã¹åã¯ç¹æ»Žã
é©åœã§ããããã®ããã«ããŠã0.03ã10ÎŒã®ã©ã
ã¯ã¹ç²åãçšããŠããªãæçšãªçµæãåŸãããã
ãã®å Žåã©ããã¯ã¹ãšã¯ãæ¬çºæç¯å²å ã§ã¯å€©ç¶
åã¯åæã®ãŽã ç²åãæ®ã«æ°Žã«åæ£ããäŸãã°ã¹
ãããŒã«åã¯ã¹ãããŒã«åã³ãã¿ãžãšã³ãããªã
éåäœç²ååã¯å ±éåäœç²åã®ãšãã«ãžãšã³åã³
ãã®ä»ã®åæ£æ¶²ã§ãããæ¬çºæã«ã¯ãç²ååã¯ç¹
滎ã¯çæ°Žæ§è¡šé¢ãæããã®ãéèŠã§ããã è©Šæ液äœãšã©ããã¯ã¹ãšã®å¹é€ã¯ã奜ãŸããã¯
é«æž©åºŠã§è¡ãªãã奜ãŸããã¯æž©åºŠ30ã40âã§ã
ãããããšããã®ããã®å Žååå¿ã¯æãè¿ éã«é²
è¡ããããã§ãããããããªãããé©åœã«å»¶é·ã
ãå¹é€æéã§ã¯ãããããäœã枩床ãåã¯å Žåã«
ãããªãè¥å¹²ããããã倧ãã枩床ã䜿çšããã
ãšãã§ããã枩床37âã§ã®äºå¹é€æéã¯ã奜ãŸã
ãã¯ïŒã15åéã§ããããã®ç¯å²ãäžããšåçŸæ§
ã¯åé¡ã§ããããã®ç¯å²ãè¶ãããšå©ç¹ã¯åŸãã
ãªãã åå¿ã¯å¥œãŸããã¯ç·©è¡æº¶æ¶²äžã§è¡ãªãããã®å Ž
åPH7.0ã9.0ãç¹ã«é©åœã§ããããšãå€æããã
奜ãŸããã¯PH7.7ã8.7ã§ãããææã®PHç¯å²ã調
ç¯ããããã«ã¯ãåèšç¯å²å ã§äœçšããä»»æã®ç·©
è¡ç©è³ªãé©åœã§ããã奜ãŸããã¯ã°ãªã·ã³ïŒé£å¡©
âç·©è¡å€ã§ãããç·©è¡å€ã®æ¿åºŠã¯å¥œãŸããã¯0.05
ã0.5Mã§ããã æ¬çºææ¹æ³ã®å®æ§çå®æœã¯ã奜ãŸããã¯æ€æ»ã
ã¹ãè©ŠæãäŸãã°è¡æŒ¿ãé©åœãªã©ããã¯ã¹ç²åæ°Ž
æžæ¿æ¶²ãšå¹é€ããããã«ããŠè¡ãªãããã®å Žå奜
ãŸããã¯åèšã®æž©åºŠåã³æéã®ç¯å²ãç¶æããã ç¶ããŠåå¿æ··åç©ããæ éã«æ¯çªãããåã¯
åã ã®å Žã«åããããŠããŠãããéæãåã¯åå
ã«èŠ³å¯ããããã«æè²ã«è²ãæœããããŠããŠãã
ãè©Šéšãã¬ãŒãäžã«æ»Žäžããè©Šéšãã¬ãŒããå圢
ã«åãããæ€æ»æ¶²äœäžã«FSãååšãããšãç²å
ã®å£å¡åãçããããã¯èçŒã§èŠãããšãã§ã
ããåå¿ãååã«èŠåŸãããã«ã¯ç²åæžæ¿æ¶²ãé
å¿åé¢ããŠãããããã®å Žååéåå¿ç²åã¯éå
éåå¿ç²åãããè¿ éãã€ãŸã容æã«æ²æ®¿ããã
奜ãŸããã¯åå¿ã¯ãã¯ã滎å®ãã¬ãŒãã§è¡ãªã€ãŠ
ããããããã¯èªåããéããããã«ä»å çã«é
å¿åé¢ããããšãã§ããã æ¹æ³ãåå®éçã«å®æœããããã«ã¯ãé£ç¶åžé
溶液ã調補ãããããå ¬ç¥éã®FSãå«æããè©Š
æãšæ¯èŒããããã®å Žå奜ãŸããã¯ãªãèçŒã§ã¿
ãããšã®ã§ããåéåå¿ãçããããæé«åžé段
éã«åå¿ã®æ€åºç¯å²ãä¹ããããã®æ€åºç¯å²ã¯ã
å ¬ç¥FSå«éãæããæšæºç©ãåžéã«ããã®ãšå
ãæ¹æ³ã§äœ¿çšããããšã«ãã枬å®ããããšãã§ã
ããå®éçã«ã¯æ¹æ³ã¯ãåé枬å®è£ 眮åã¯å 床èš
ã®äœ¿çšã§è¡ãªãããšãã§ããã æ¬çºææ¹æ³ã«ãã€ãŠæž¬å®ããããšã®ã§ãããã€
ããªã³ãšã¯ããããã溶解æ§ãã€ããªã³ãã€ãŸã
ãã€ããªã³ã¢ãããŒãæ¢ã«äžç·ã«ãªã€ããã€ããª
ã³ã«ãªã€ãããè¡šé¢ã«ãªãçæ£ã®ãã€ããªã³ã¢ã
ããŒãæãããåã¯ãã¥ãã«ãããã€ããªã³ã¢ã
ããŒã®ããã«æåãããã€ããªã³ã®äžé圢ã§ã
ãããã®æº¶è§£æ§ãã€ããªã³ã«ãã€ãŠåãããã«ã
ãŠåãåéåå¿ãåŸãããããæ åãããã«ããŠ
ææ¡ãããã ã©ããã¯ã¹ã¯ã奜ãŸããã¯ç²åå«é0.1ã10ïŒ ã
ç¹ã«0.5ãïŒïŒ ãæãããã©ããã¯ã¹ãšè©Šæ溶液
ãšã¯ã容éå²åçŽïŒïŒ10ã10ïŒïŒã§æ··åãããïŒ
ïŒ ã®æžæ¿æ¶²ã䜿çšããå Žåã«ã¯ãæ··åå²åã¯å¥œãŸ
ããã¯ïŒïŒïŒãïŒïŒïŒã§ããã æ¬çºæã¯ããã€ããªãã²ã³ãçŽæ¥ã«æž¬å®ããã
ãã«ãé©åœã§ããããã®å Žåã«ã¯ãè©Šæã®ãã€ã
ãªãã²ã³å šéšããå ã¥å ¬ç¥æ¹æ³ã§ãã€ããªã³ã¢ã
ããŒã«å€æãããå€æã¯ãé©åœãªé µçŽ ã§è¡ãªãã
é©åœãªé µçŽ ã¯äŸãã°ããã³ãã³åã¯èæ¯ãäŸãã°
ãããããœãã³ïŒBatroxobinïŒã§ãããå¹³è¡è©Š
æã§æŽã«ãã€ããªã³ã¢ãããŒã®å«éã確ãããå Ž
åã«ã¯ãæ¯èŒè©Šæäžã®æž¬å®FSå«éãšé µçŽ åŠçã®
è©Šæãšã®éã®å·®ç°ãããã€ããªãã²ã³å«éãåŸã
ããã奜ãŸããã¯æ¬çºæã®ãã®å®æœåœ¢åŒã§ã¯ãã
ã€ããªãã²ã³ã®ãã€ããªã³ã¢ãããŒãžã®å€æã¯ã©
ããã¯ã¹ç²åã®ååšã§è¡ãªãã 次ã«å®æœäŸã«ã€ãæ¬çºæã説æããã äŸ ïŒ (A) å¥åº·ãªäººããEDTA1mgïŒmlåã³ã¢ãããã
ã³0.1mgïŒmlã®ååšäžã«è¡æ¶²ããšãã2000gã§10
åéé å¿åé¢ãããè¡æŒ¿ããã®äžæŸã¿ïŒmlã37
âã«ããããã³ãã³ããªãã¹ã¿ãžã³
ïŒopostasinïŒãããã·ãŠç€Ÿã0.05åäœãšæ··åã
ãã0.2mlã®æŽé€éãååºããäºãæºåããã
ããªã³ããªã¯ãšãã³ïŒLiqueminïŒãããã·ãŠ
瀟ãïŒåäœåã³ãã«ãžã³ãã·ã°ãïŒSigmaïŒã
0.2åäœãå«æããå°ç®¡ã«ããããã§ãšããæŽ
é€éã®ååºãã®æç¹ãšããŠã¯ã次ã®æéãéžã
ã ïŒããã³ãã³ã®æ·»å çŽåŸã30ç§ãïŒåãïŒå
åã³ïŒåããã®ããã«ããŠãçš®ã ã®éã®FSã
å«æããè©ŠæãåŸãããããã¯ä»ã®æ€æ»ã«å®€æž©
ã§ä¿åããã (B) è©Šæã®åžé溶液ããã°ãªã·ã³0.25ã¢ã«åã³
NaCl0.9ïŒ ãå«æãã1nâNaOHã§PH8.2ã«èª¿
ç¯ããã°ãªã·ã³ïŒNaClâç·©è¡å€ã§èª¿è£œããã
å¹³åç²åŸ0.8ÎŒãæãã10ïŒ ã®æžæ¿æ¶²ã®åœ¢ã®ããª
ã¹ãããŒã«ã©ããã¯ã¹ãã»ã«ãïŒServaïŒç€Ÿã
ãã€ãã«ãã«ã¯åšããããã®ç·©è¡å€ã§ïŒïŒ10ã«
åžéãããããããã©ããã¯ã¹0.05mlåã³é©åœ
ãªæ¹æ³ã§äºãåžéããè¡æŒ¿è©Šæ0.05mlãæ··å
ãã37âã§10åéå¹é€ãããå°ç®¡ã®å 容ãæè²
ã«çè²ãããã©ã¹ããã¯ãã¬ãŒãã®çžäºã«å¥ã
ã«åé¢ããå Žã«å¡åžãããã¬ãŒããæ éã«ïŒå
éå転ããç¶ããŠã©ããã¯ã¹ç²åã®å£å¡åãèš
é²ãããè¡æŒ¿ã«å¯Ÿããããã³ãã³ã®äœçšæéã
å¢å€§ããã«ã€ããŠãå£å¡åã®åŒ·åºŠã倧ãããªã
ããšãå€æãããå¢å€§ããåžéã䜿çšããããš
ã«ãã€ãŠããã¹ãŠã®è©Šæã«ãªãæãããªåéå
å¿ãçããåžé溶液ãçããããããšãã§ã
ããçµæã¯ç¬¬ïŒè¡šã«èšèŒãããŠããã
ãè¡šã
ç·©è¡å€åã¯è¡æž
ã§å®æœãã察ç
§ç©ã¯åéåå¿ã
çããªãã äŸ ïŒ äŸïŒã«ãã€ãŠèª¿è£œããFSå«æè©Šæããã°ãªã·
ã³ïŒNaClãå«æããç·©è¡å€ã§åžéããããã«ä»
å çã«çã®è¡æž ã¢ã«ããã³ïŒïŒ ãæ·»å ãããçµæ
ã¯ç¬¬ïŒè¡šã«èšèŒãããŠããã
çããªãã äŸ ïŒ äŸïŒã«ãã€ãŠèª¿è£œããFSå«æè©Šæããã°ãªã·
ã³ïŒNaClãå«æããç·©è¡å€ã§åžéããããã«ä»
å çã«çã®è¡æž ã¢ã«ããã³ïŒïŒ ãæ·»å ãããçµæ
ã¯ç¬¬ïŒè¡šã«èšèŒãããŠããã
ãè¡šã
äŸ ïŒ
ãã³ïŒMahnïŒãã®ä»ïŒThromb.Res.第14å·»ã
第651ã663é ïŒ1979幎ïŒã®åŠæ¹ã«ãã€ãŠãFSã
å°¿çŽ ïŒã¢ã«ãããªã¹50mã¢ã«ãEDTA5mã¢ã«ã
ã¢ããããã³0.01ïŒ ã«ãšããã溶液ïŒPH7.4ïŒã
調補ããFSã®å«éãã0.1nâNaOHã§åžéãã
åŸã«å åŠå¯åºŠ280nmã§æž¬å®ãããäŸïŒã«ãã€ãŠåŸ
ãããè¡æŒ¿ããã°ãªã·ã³ïŒNaClïŒPH8.2ïŒã§ïŒïŒ
ïŒã«åžéãããå¢å€§éã®å°¿çŽ å«æFS溶液ãæ·»å
ããããšã«ãããFSã®äžå®å«éã®è©Šæã調補ã
ãïŒå³ã¡ïŒãïŒã10åã³50ÎŒgïŒmlããã®å Žå容
éã®åè¡¡ã¯FSãå«ãŸãªãå°¿çŽ æº¶æ¶²ã«ãã€ãŠè¡ãª
ããè©ŠæãäŸïŒã«çžå¿ããŠã©ããã¯ã¹æžæ¿æ¶²ãšå¹
é€ãããããããªãåéåå¿ãçããæåŸã®åžé
段éã確ããããïŒã€ã®ç¬ç«ãã枬å®ããã®çµæ
ã¯ã第ïŒè¡šã«èšèŒãããŠããã
第651ã663é ïŒ1979幎ïŒã®åŠæ¹ã«ãã€ãŠãFSã
å°¿çŽ ïŒã¢ã«ãããªã¹50mã¢ã«ãEDTA5mã¢ã«ã
ã¢ããããã³0.01ïŒ ã«ãšããã溶液ïŒPH7.4ïŒã
調補ããFSã®å«éãã0.1nâNaOHã§åžéãã
åŸã«å åŠå¯åºŠ280nmã§æž¬å®ãããäŸïŒã«ãã€ãŠåŸ
ãããè¡æŒ¿ããã°ãªã·ã³ïŒNaClïŒPH8.2ïŒã§ïŒïŒ
ïŒã«åžéãããå¢å€§éã®å°¿çŽ å«æFS溶液ãæ·»å
ããããšã«ãããFSã®äžå®å«éã®è©Šæã調補ã
ãïŒå³ã¡ïŒãïŒã10åã³50ÎŒgïŒmlããã®å Žå容
éã®åè¡¡ã¯FSãå«ãŸãªãå°¿çŽ æº¶æ¶²ã«ãã€ãŠè¡ãª
ããè©ŠæãäŸïŒã«çžå¿ããŠã©ããã¯ã¹æžæ¿æ¶²ãšå¹
é€ãããããããªãåéåå¿ãçããæåŸã®åžé
段éã確ããããïŒã€ã®ç¬ç«ãã枬å®ããã®çµæ
ã¯ã第ïŒè¡šã«èšèŒãããŠããã
ãè¡šã
ãªãéœæ§ã®åéåå¿ãããããåã
ã®ç¯å²ã®åž
éãããFSã®æ€åºç¯å²ããåã FSã®æ¿åºŠã«åžé
床ãä¹ããããšã«ããèšç®ããããšãã§ãããå¹³
åããŠãæ€åºç¯å²çŽ1.2ÎŒgïŒmlãåŸãããã äŸ ïŒ äººéã®ã¯ãšã³é žå¡©è¡æŒ¿å«é500mgïŒdlåã³ãã€
ããªãã²ã³å«é180mgïŒdlãæãããã€ããªãã²
ã³æº¶æ¶²ããçã®è¡æž ã¢ã«ããã³ïŒïŒ ãå«æããã°
ãªã·ã³ïŒNaClâç·©è¡å€ïŒPH8.2ïŒã§ïŒïŒ100ã«åž
éãããããããåºçºããŠãæŽã«é£ç¶åžé床ïŒïŒ
ïŒãïŒïŒïŒãã®ä»ããã®ç·©è¡å€ã§èª¿è£œããããã
ããããã0.1mlãå°ç®¡ã«ããããã§ãšããåã
ã®å°ç®¡ã«ãé 次ã«0.9ïŒ ã®NaCl溶液ã§ïŒïŒ10ã«äº
ãåžéãããããããœãã³ïŒBatroxobinïŒ
ãReptilaseâReagenzãããŒãªã³ã¬ãŒç€Ÿããã³
ãã€ã åšãã®æº¶æ¶²ãããã0.1mlåã³äŸïŒã«ãã€
ãŠèª¿è£œããã©ããã¯ã¹0.1mlãããããã§ãšãã
37âã§10åéå¹é€ãããç¶ããŠè©Šéšãã¬ãŒãã«æ»Ž
äžããããšã«ãã€ãŠåéåå¿å䟡ã枬å®ãããã
ã€ããªãã²ã³æº¶æ¶²ã«ã¯ïŒïŒ16ããè¡æŒ¿ã«ã¯ïŒïŒïŒ
ãåŸãããããã¯äºåžéïŒïŒ100ãèæ ®ãããšã
ïŒïŒ1600åã¯ïŒïŒ800ã®åžéã«çžå¿ãããããã
ãããã€ããªãã²ã³ã®æ€åºç¯å²çŽ2.7ÎŒgïŒmlãèš
ç®ãããã äŸ ïŒ äŸïŒã«ãã€ãŠèª¿è£œãããã³ãã³ã§ïŒåéåŠçã
ãè¡æŒ¿ã®çã®è¡æž ã¢ã«ããã³å«æã°ã«ã·ã³ïŒ
NaClâç·©è¡æ¶²ã§ã®åžé溶液ããã©ããã¯ã¹æžæ¿
液ãš37âã§çš®ã ã®æéå¹é€ãã次ãã§åéåå¿å
䟡ã枬å®ãããããããªãããæ床ã¯å¹é€æé10
åéåŸã«ãã¯ãäžããªãããšãå€æããã äŸ ïŒ äŸïŒã«çžå¿ããŠãå°¿çŽ ïŒã¢ã«ã«ãšãããFS溶
液ã調補ãããã°ãªã·ã³ïŒNaClâç·©è¡å€ïŒPH
8.2ïŒã«ãšããããã€ããªãã²ã³å«éïŒmgïŒmlã
æãããã€ããªãã²ã³æº¶æ¶²ãïŒÃ1mã«åå²ãã
37âã«ããæŽé€éã«å¢å€§éã®FS溶液ãå ãããšã
10ã20ã30ã40ãåã³50ÎŒgïŒmlã®å«éãçããã éåžžè¡å°æ¿ã®åéã枬å®ããã®ã«äœ¿çšããåžå Ž
ãåŸãããã¬ã³ãŒããŒãæããåé枬å®æ©ããã©
ãŠã³ïŒã¡ã«ãºã³ã²ã³ïŒBraunïŒMelsungenïŒç€Ÿ
補ãã«åŸãã調ç¯ããããšã®ã§ããæ¹æè£ çœ®ãå
ããã 次ã®èª¿è£œãè¡ãªãïŒãã€ã«ã¿ãŒ546nmã37âã
æ¹æé床500r.p.mãã°ãªã·ã³ïŒNaClâç·©è¡å€ïŒ
mlãè£ å ¥ãã枩床ã®é©å床ã37âã«ãããããã«
ã°ãªã·ã³ïŒNaClâç·©è¡å€ã«ãšãããïŒïŒ ã®ã©ã
ãã¯ã¹æžæ¿æ¶²0.1mlãæ·»å ããå 床èšã§åžå 床1.9
ã調ç¯ãããåè¿°ã®FSå«æãã€ããªãã²ã³æº¶æ¶²
50ÎŒlãæ·»å ãããã©ããã¯ã¹ç²åã®å£å¡åã«ãã€
ãŠæº¶æ¶²ã®æŸæåãçããããã¯ã¬ã³ãŒããŒã«ãã€
ãŠç€ºããããå®éšããé 次ã«ãã€ããªãã²ã³æº¶æ¶²
ãå«ã¿FSã®æ·»å ãæããªãã§FSã®ãã¹ãŠã®æ¿åºŠ
ã§è¡ãªãã䜿çšãããã€ããªãã²ã³æº¶æ¶²ã¯ãæ¢ã«
äžå®å«éã®FSãå«æããããšãå€æããããã
ãšããã®ãFSã®æ·»å ãæããªããŠãæ¢ã«æº·æ¿ã®
æŸæåãç«èšŒãããããã§ãããåé枬å®æ©ã®åž
å 床ã®æ倧æžå°ã¯FSã®æ¿åºŠã«å¯ŸããŠèª²ãããã
ãã®å ŽåçŽç·ç¶ã®é¢ä¿ãåŸããããã®é¢ä¿ããå¢
倧ãšããŠã®åå¿æ床ãèªåãããšãã§ããã
FS14mEïŒÎŒgãèŠåºããããæŽã«ãã®å¢å€§ã¯ã䜿
çšãããã€ããªãã²ã³æº¶æ¶²äžã«æ¢ã«å«ãŸããFS
ã枬å®ããã®ã«äœ¿çšããããšãã§ããïŒãã€ããª
ãã²ã³å«é51ÎŒgïŒmlïŒ2.6ïŒ ïŒãèŠåºãããã äŸ ïŒ ã°ãããïŒååã³ã¬ã³ãŒãã®ã¯ããã亀代èªå
æ©ãåããåžå Žã§åŸãããå 床èšã§æ¬¡ã®èª¿è£œãè¡
ãªãïŒãã€ã«ã¿ãŒ405nmã37âãã»ããã¯ãã¯ã
ããã ã¯ãããïŒåã«ã°ãªã·ã³ïŒNaClâè¡æž ã¢ã«ã
ãã³âç·©è¡å€ïŒPH8.2ïŒããããïŒmlãå å¡«ãã
枩床ã37âã«ãããã¯ãããïŒãïŒäžã«ãäŸïŒã«
ãã€ãŠèª¿è£œããããã³ãã³åŠçã®è¡æŒ¿è©Šæããã
ã100ÎŒãå ¥ããæ··åããã次ãã§åã ã®ãã
ãã«ãã°ãªã·ã³ïŒNaClâç·©è¡å€ïŒPH8.2ïŒã§0.5ïŒ
ã«äºãåžéããã©ããã¯ã¹æžæ¿æ¶²ãã»ã«ã
ïŒServaïŒãå¹³åç²åŸ0.085ÎŒïŒ0.1mlãæ·»å ããæ··å
ããåæã«ã¯ããã亀代æ©äžŠã³ã«ã¬ã³ãŒããŒãæ
äœããããããã¯ãããã³ãã³ã§ã®åŠçæéã«é¢
é£ããŠçŽç·ç¶ã®åžå 床ã®å¢å€§ã瀺ããããã¯ç¬¬ïŒ
è¡šã«èšèŒãããŠããã
éãããFSã®æ€åºç¯å²ããåã FSã®æ¿åºŠã«åžé
床ãä¹ããããšã«ããèšç®ããããšãã§ãããå¹³
åããŠãæ€åºç¯å²çŽ1.2ÎŒgïŒmlãåŸãããã äŸ ïŒ äººéã®ã¯ãšã³é žå¡©è¡æŒ¿å«é500mgïŒdlåã³ãã€
ããªãã²ã³å«é180mgïŒdlãæãããã€ããªãã²
ã³æº¶æ¶²ããçã®è¡æž ã¢ã«ããã³ïŒïŒ ãå«æããã°
ãªã·ã³ïŒNaClâç·©è¡å€ïŒPH8.2ïŒã§ïŒïŒ100ã«åž
éãããããããåºçºããŠãæŽã«é£ç¶åžé床ïŒïŒ
ïŒãïŒïŒïŒãã®ä»ããã®ç·©è¡å€ã§èª¿è£œããããã
ããããã0.1mlãå°ç®¡ã«ããããã§ãšããåã
ã®å°ç®¡ã«ãé 次ã«0.9ïŒ ã®NaCl溶液ã§ïŒïŒ10ã«äº
ãåžéãããããããœãã³ïŒBatroxobinïŒ
ãReptilaseâReagenzãããŒãªã³ã¬ãŒç€Ÿããã³
ãã€ã åšãã®æº¶æ¶²ãããã0.1mlåã³äŸïŒã«ãã€
ãŠèª¿è£œããã©ããã¯ã¹0.1mlãããããã§ãšãã
37âã§10åéå¹é€ãããç¶ããŠè©Šéšãã¬ãŒãã«æ»Ž
äžããããšã«ãã€ãŠåéåå¿å䟡ã枬å®ãããã
ã€ããªãã²ã³æº¶æ¶²ã«ã¯ïŒïŒ16ããè¡æŒ¿ã«ã¯ïŒïŒïŒ
ãåŸãããããã¯äºåžéïŒïŒ100ãèæ ®ãããšã
ïŒïŒ1600åã¯ïŒïŒ800ã®åžéã«çžå¿ãããããã
ãããã€ããªãã²ã³ã®æ€åºç¯å²çŽ2.7ÎŒgïŒmlãèš
ç®ãããã äŸ ïŒ äŸïŒã«ãã€ãŠèª¿è£œãããã³ãã³ã§ïŒåéåŠçã
ãè¡æŒ¿ã®çã®è¡æž ã¢ã«ããã³å«æã°ã«ã·ã³ïŒ
NaClâç·©è¡æ¶²ã§ã®åžé溶液ããã©ããã¯ã¹æžæ¿
液ãš37âã§çš®ã ã®æéå¹é€ãã次ãã§åéåå¿å
䟡ã枬å®ãããããããªãããæ床ã¯å¹é€æé10
åéåŸã«ãã¯ãäžããªãããšãå€æããã äŸ ïŒ äŸïŒã«çžå¿ããŠãå°¿çŽ ïŒã¢ã«ã«ãšãããFS溶
液ã調補ãããã°ãªã·ã³ïŒNaClâç·©è¡å€ïŒPH
8.2ïŒã«ãšããããã€ããªãã²ã³å«éïŒmgïŒmlã
æãããã€ããªãã²ã³æº¶æ¶²ãïŒÃ1mã«åå²ãã
37âã«ããæŽé€éã«å¢å€§éã®FS溶液ãå ãããšã
10ã20ã30ã40ãåã³50ÎŒgïŒmlã®å«éãçããã éåžžè¡å°æ¿ã®åéã枬å®ããã®ã«äœ¿çšããåžå Ž
ãåŸãããã¬ã³ãŒããŒãæããåé枬å®æ©ããã©
ãŠã³ïŒã¡ã«ãºã³ã²ã³ïŒBraunïŒMelsungenïŒç€Ÿ
補ãã«åŸãã調ç¯ããããšã®ã§ããæ¹æè£ çœ®ãå
ããã 次ã®èª¿è£œãè¡ãªãïŒãã€ã«ã¿ãŒ546nmã37âã
æ¹æé床500r.p.mãã°ãªã·ã³ïŒNaClâç·©è¡å€ïŒ
mlãè£ å ¥ãã枩床ã®é©å床ã37âã«ãããããã«
ã°ãªã·ã³ïŒNaClâç·©è¡å€ã«ãšãããïŒïŒ ã®ã©ã
ãã¯ã¹æžæ¿æ¶²0.1mlãæ·»å ããå 床èšã§åžå 床1.9
ã調ç¯ãããåè¿°ã®FSå«æãã€ããªãã²ã³æº¶æ¶²
50ÎŒlãæ·»å ãããã©ããã¯ã¹ç²åã®å£å¡åã«ãã€
ãŠæº¶æ¶²ã®æŸæåãçããããã¯ã¬ã³ãŒããŒã«ãã€
ãŠç€ºããããå®éšããé 次ã«ãã€ããªãã²ã³æº¶æ¶²
ãå«ã¿FSã®æ·»å ãæããªãã§FSã®ãã¹ãŠã®æ¿åºŠ
ã§è¡ãªãã䜿çšãããã€ããªãã²ã³æº¶æ¶²ã¯ãæ¢ã«
äžå®å«éã®FSãå«æããããšãå€æããããã
ãšããã®ãFSã®æ·»å ãæããªããŠãæ¢ã«æº·æ¿ã®
æŸæåãç«èšŒãããããã§ãããåé枬å®æ©ã®åž
å 床ã®æ倧æžå°ã¯FSã®æ¿åºŠã«å¯ŸããŠèª²ãããã
ãã®å ŽåçŽç·ç¶ã®é¢ä¿ãåŸããããã®é¢ä¿ããå¢
倧ãšããŠã®åå¿æ床ãèªåãããšãã§ããã
FS14mEïŒÎŒgãèŠåºããããæŽã«ãã®å¢å€§ã¯ã䜿
çšãããã€ããªãã²ã³æº¶æ¶²äžã«æ¢ã«å«ãŸããFS
ã枬å®ããã®ã«äœ¿çšããããšãã§ããïŒãã€ããª
ãã²ã³å«é51ÎŒgïŒmlïŒ2.6ïŒ ïŒãèŠåºãããã äŸ ïŒ ã°ãããïŒååã³ã¬ã³ãŒãã®ã¯ããã亀代èªå
æ©ãåããåžå Žã§åŸãããå 床èšã§æ¬¡ã®èª¿è£œãè¡
ãªãïŒãã€ã«ã¿ãŒ405nmã37âãã»ããã¯ãã¯ã
ããã ã¯ãããïŒåã«ã°ãªã·ã³ïŒNaClâè¡æž ã¢ã«ã
ãã³âç·©è¡å€ïŒPH8.2ïŒããããïŒmlãå å¡«ãã
枩床ã37âã«ãããã¯ãããïŒãïŒäžã«ãäŸïŒã«
ãã€ãŠèª¿è£œããããã³ãã³åŠçã®è¡æŒ¿è©Šæããã
ã100ÎŒãå ¥ããæ··åããã次ãã§åã ã®ãã
ãã«ãã°ãªã·ã³ïŒNaClâç·©è¡å€ïŒPH8.2ïŒã§0.5ïŒ
ã«äºãåžéããã©ããã¯ã¹æžæ¿æ¶²ãã»ã«ã
ïŒServaïŒãå¹³åç²åŸ0.085ÎŒïŒ0.1mlãæ·»å ããæ··å
ããåæã«ã¯ããã亀代æ©äžŠã³ã«ã¬ã³ãŒããŒãæ
äœããããããã¯ãããã³ãã³ã§ã®åŠçæéã«é¢
é£ããŠçŽç·ç¶ã®åžå 床ã®å¢å€§ã瀺ããããã¯ç¬¬ïŒ
è¡šã«èšèŒãããŠããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ çç©åŠç液äœã®ãã€ããªã³ã¢ãããŒãæ€åºå
ã³æž¬å®ããæ¹æ³ã«ãããŠãè©Šæ液äœãçæ°Žæ§ã©ã
ãã¯ã¹ãšå¹é€ããåéåå¿ã枬å®ããããšãç¹åŸŽ
ãšãããã€ããªã³ã¢ãããŒãæ€åºåã³æž¬å®ããæ¹
æ³ã ïŒ å¹³åç²åŸ0.05ã1.5ÎŒãæããçæ°Žæ§ã©ããã¯
ã¹ã䜿çšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ å¹é€ããé«æž©åºŠã§è¡ãªãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒ
é åã¯ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ æž©åºŠ30ã40âã§ïŒã15åéå¹é€ããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ ç·©è¡æº¶æ¶²äžã§PH7.0ã9.0ã§å¹é€ããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé ãã第ïŒé ãŸã§ã®ããããïŒé èšèŒ
ã®æ¹æ³ã ïŒ å®æ§çã«å®æœããããã«ãè©Šæãã©ããã¯ã¹
ãšå¹é€ããåŸã«æè²ã®è©Šéšãã¬ãŒãã«å¡åžããå
éåå¿ã確ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ãã第ïŒ
é ãŸã§ã®ããããïŒé èšèŒã®æ¹æ³ã ïŒ å®éçã«å®æœããããã«ãè©Šæ液äœã®é£ç¶åž
é溶液ã調補ããFSã®å ¬ç¥å«éã®æšæºãšæ¯èŒã
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ãã第ïŒé ãŸã§ã®ãã¥ã
ãïŒé èšèŒã®æ¹æ³ã ïŒ å®éçã«å®æœããããã«ãå åŠçæ¹æ³ãçšã
ãŠåéåå¿ã«ãã€ãŠæ¹èµ·ãã溷æ¿ã®å€åã枬å®ã
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ãã第ïŒé ãŸã§ã®ãã¥ã
ãïŒé èšèŒã®æ¹æ³ã ïŒ è©Šæ液äœäžã«ååšãããã€ããªãã²ã³ããå
ã¥å ¬ç¥æ¹æ³ã§ããã³ãã³åã¯èæ¯é µçŽ ã§FSã«å€
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ãã第ïŒé ãŸã§ã®ãã
ããïŒé èšèŒã®æ¹æ³ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19803017707 DE3017707A1 (de) | 1980-05-08 | 1980-05-08 | Verfahren und reagens zum nachweis von fibrinmonomer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS574551A JPS574551A (en) | 1982-01-11 |
| JPS6360862B2 true JPS6360862B2 (ja) | 1988-11-25 |
Family
ID=6101941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6838181A Granted JPS574551A (en) | 1980-05-08 | 1981-05-08 | Method of and reagent for detecting fibrinmonomer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4429040A (ja) |
| EP (1) | EP0039885B1 (ja) |
| JP (1) | JPS574551A (ja) |
| AT (1) | ATE7542T1 (ja) |
| DD (1) | DD158954A5 (ja) |
| DE (2) | DE3017707A1 (ja) |
| ES (1) | ES8202639A1 (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3330699A1 (de) * | 1983-08-25 | 1985-03-07 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur gleichzeitigen bestimmung von fibrinogen und fibrinogen-spaltprodukten im plasma |
| AU4158785A (en) * | 1984-03-26 | 1985-11-01 | International Health Services | A method of determining the clotting time of blood and particulate reagents therefor |
| DE3430906A1 (de) * | 1984-08-22 | 1986-02-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur bestimmung von fibrinmonomer in plasma |
| DD261844A1 (de) * | 1986-07-09 | 1988-11-09 | Adw Ddr | Verfahren zur praezipitation von fibrinmonomeren |
| US4921787A (en) * | 1987-05-01 | 1990-05-01 | Cambridge Bioscience Corporation | Detection of antibodies to human immunodeficiency virus by agglutination of antigen coated latex |
| AU644205B2 (en) * | 1990-08-23 | 1993-12-02 | New York Blood Center, Inc., The | Assays using a soluble fibrin-like monomer |
| CN1091315A (zh) * | 1992-10-08 | 1994-08-31 | E·R·æ¯å¥åžç¶åå ¬åž | è¡çº€ç»Žèçœå°éåç»åç©åå ¶äœ¿çšæ¹æ³ |
| WO1996016713A1 (en) * | 1994-12-02 | 1996-06-06 | E.R. Squibb And Sons, Inc. | Centrifuge reagent delivery system |
| US5733446A (en) * | 1994-12-02 | 1998-03-31 | Bristol-Myers Squibb Company | Centrifuge with annular filter |
| PL320511A1 (en) * | 1994-12-02 | 1997-10-13 | Bristol Myers Squibb Co | Method of and apparatus for isolating fibrin i from blood plasma |
| DE19756773A1 (de) * | 1997-12-19 | 1999-06-24 | Dade Behring Marburg Gmbh | Neues Verfahren und Diagnosemittel zur HÀmostase-Diagnostik |
| RU2298798C1 (ru) * | 2006-01-17 | 2007-05-10 | ÐбÑеÑÑвП Ñ ÐŸÐ³ÑаМОÑеММПй ПÑвеÑÑÑвеММПÑÑÑÑ "ÐОПÑОп-ÐМалОÑОка" (ÐÐÐ "ÐОПÑОп-ÐМалОÑОка") | СпПÑПб кПМÑÑÐŸÐ»Ñ Ð±ÐžÐŸÐ»ÐŸÐ³ÐžÑеÑкПй пÑÐŸÐ±Ñ Ð² ÑеакÑОО лаÑекÑ-агглÑÑОМаÑОО О аМалОÑОÑеÑÐºÐ°Ñ ÑОÑÑеЌа ÐŽÐ»Ñ ÐµÐ³ÐŸ ПÑÑÑеÑÑÐ²Ð»ÐµÐœÐžÑ |
| CA3153941A1 (en) * | 2019-10-17 | 2021-04-22 | Mary POMEROY | Coagulation assay apparatus and methods thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3088875A (en) | 1959-10-27 | 1963-05-07 | Hyland Lab | Immunological diagnostics utilizing polystyrene latex particles of 0.15 to 0.25 micron |
| GB1362776A (en) * | 1970-07-17 | 1974-08-07 | Wellcome Found | Immunological reagent |
| NL7602422A (nl) * | 1976-03-08 | 1977-09-12 | Leuven Res & Dev Vzw | Trombosetest. |
| US4208185A (en) | 1976-08-16 | 1980-06-17 | Mitsubishi Chemical Industries Limited | Method and apparatus for the measurement of antigens and antibodies |
| US4090846A (en) * | 1976-10-20 | 1978-05-23 | Fisher Scientific Company | Indirect latex test for determination of fibrinogen degradation products |
| CA1101330A (en) | 1977-09-19 | 1981-05-19 | Ernst A. Fischer | Immunological material bonded to carboxylated latex polymer and process for making it |
-
1980
- 1980-05-08 DE DE19803017707 patent/DE3017707A1/de not_active Withdrawn
-
1981
- 1981-04-14 ES ES501364A patent/ES8202639A1/es not_active Expired
- 1981-04-21 US US06/256,212 patent/US4429040A/en not_active Expired - Fee Related
- 1981-05-04 DD DD81229722A patent/DD158954A5/de not_active IP Right Cessation
- 1981-05-05 DE DE8181103395T patent/DE3163585D1/de not_active Expired
- 1981-05-05 EP EP81103395A patent/EP0039885B1/de not_active Expired
- 1981-05-05 AT AT81103395T patent/ATE7542T1/de not_active IP Right Cessation
- 1981-05-08 JP JP6838181A patent/JPS574551A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| EP0039885A1 (de) | 1981-11-18 |
| ES501364A0 (es) | 1982-02-16 |
| DE3163585D1 (en) | 1984-06-20 |
| JPS574551A (en) | 1982-01-11 |
| DE3017707A1 (de) | 1981-11-12 |
| US4429040A (en) | 1984-01-31 |
| ES8202639A1 (es) | 1982-02-16 |
| DD158954A5 (de) | 1983-02-09 |
| ATE7542T1 (de) | 1984-06-15 |
| EP0039885B1 (de) | 1984-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3088875A (en) | Immunological diagnostics utilizing polystyrene latex particles of 0.15 to 0.25 micron | |
| US3915805A (en) | Quantitative detection of endotoxin in biological fluids | |
| CA1139203A (en) | Method and reagent for counteracting lipemic interference | |
| US4038147A (en) | Method for detecting endotoxins | |
| EP0064274B1 (en) | Method for assaying antigen-antibody reactions and reagent therefor | |
| JPH01163662A (ja) | æåããã³ïŒåã¯æäœã®æ€åºæ¹æ³ããã³æ€åºçšã®è©Šéšããã | |
| US3912805A (en) | Reagent and assay for human fibrinogen degradation products | |
| US4436825A (en) | Process and reagents for antibody detection involving erythrocyte agglutination | |
| US4429040A (en) | Method and reagent for the detection of fibrin monomer | |
| US4605686A (en) | Latex for immunoserological tests and a method for the production of the same | |
| SU1091844A3 (ru) | ÐОагМПÑÑОкÑÐŒ Ўл Ð²Ñ Ð²Ð»ÐµÐœÐž аМÑОгеМа гепаÑОÑа Ð | |
| CA1168580A (en) | Immunological reagent for the detection of tubes of the rheumatoid factor in a biological specimen and process for preparing this novel reagent | |
| CA1248433A (en) | Process and reagent for the determination of fibrin monomer in plasma | |
| IE66587B1 (en) | Enzymatic assay kit and method applicable to whole cells | |
| JP3786543B2 (ja) | å ç«åŠç枬å®è©Šè¬ | |
| JP3618797B2 (ja) | å ç«æž¬å®æ³ | |
| EP0186476A2 (en) | Diagnostic kit and method for assaying blood components | |
| JPH09266798A (ja) | ããã³ãã³æŽ»æ§ã®æž¬å®æ³ããã³åéè©Šè¬ | |
| US3697639A (en) | Serological test for the detection of hepatitis | |
| Harmoinen et al. | Fibrinogen: a comparison of an immunoturbidimetric method with four conventional methods | |
| JP3559865B2 (ja) | ãã£ããªã³ã¢ãããŒã®æž¬å®æ³ | |
| JPH0456258B2 (ja) | ||
| SU1707537A1 (ru) | СпПÑПб ПпÑеЎелеМО ÑПкÑОÑМПÑÑО жОЎкПÑÑО | |
| JPH07104352B2 (ja) | ãªã¥ãŠããå åæ€åºçšã®æ°èŠç·©è¡å€åã³ãã®æ¹æ³ | |
| Wenz et al. | Improved method for detecting hemagglutination by centrifugal analysis. |